NASDAQ:ACON Aclarion Q1 2026 Earnings Report $2.34 -0.04 (-1.68%) Closing price 10/5/2026 04:00 PM EasternExtended Trading$2.40 +0.06 (+2.74%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aclarion EPS ResultsActual EPS-$1.34Consensus EPS -$1.55Beat/MissBeat by +$0.21One Year Ago EPSN/AAclarion Revenue ResultsActual Revenue$0.02 millionExpected Revenue$0.03 millionBeat/MissMissed by -$3.86 thousandYoY Revenue GrowthN/AAclarion Announcement DetailsQuarterQ1 2026Date5/13/2026TimeBefore Market OpensConference Call DateWednesday, May 13, 2026Conference Call Time7:00AM ETUpcoming EarningsAclarion's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Aclarion Earnings HeadlinesHealth Catalyst (NASDAQ:HCAT) and Aclarion (NASDAQ:ACON) Critical AnalysisOctober 3 at 4:58 AM | americanbankingnews.comAclarion (NASDAQ:ACON) versus Veeva Systems (NYSE:VEEV) Financial AnalysisOctober 2, 2026 | americanbankingnews.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven SitesSeptember 29, 2026 | globenewswire.comAclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial SiteAugust 20, 2026 | globenewswire.comTop Aclarion Executive Makes Bold Insider Move on Company StockAugust 18, 2026 | tipranks.comSee More Aclarion Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email. Email Address About AclarionAclarion (NASDAQ:ACON) (NASDAQ: ACON) is a healthcare technology company focused on improving the diagnosis and treatment of chronic low back pain. The company develops tools intended to help physicians identify the spinal discs that may be contributing to a patient’s pain and support more informed treatment decisions. Its principal product, Nociscan, is a cloud-based platform that analyzes data from magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI). By combining imaging information with proprietary algorithms and biochemical biomarkers, the platform is designed to provide physicians with additional objective information about disc health and potential pain generators. Aclarion was formerly known as Nocimed and adopted the Aclarion name as it expanded its focus on data-driven spine care. The company markets its technology to healthcare providers and spine specialists in the United States and internationally. Its solutions are intended to complement, rather than replace, clinical evaluation and existing diagnostic imaging.View Aclarion ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
